melanocortin is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-06-17. Numbers and descriptions here follow the published literature rather than marketing material.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.
After subcutaneous dosing, peak plasma concentrations appear within roughly one hour, and elimination is fast, with a half-life on the order of a few hours. Degradation is mainly proteolytic, and at least one circulating fragment retains receptor activity, so parent-drug levels alone do not describe total exposure. Clearance does not depend heavily on hepatic cytochrome enzymes, which lowers the likelihood of common metabolic interaction routes. Data in renal or hepatic impairment are limited. Repeated dosing does not appear to produce marked accumulation given the short half-life.
Reported pharmacodynamic effects include transient rises in blood pressure and heart rate, flushing, nausea and headache, appearing soon after dosing and resolving within hours. These responses were dose-related in early studies and shaped the label's cardiovascular cautions and blood pressure monitoring advice. Gastrointestinal upset is the most frequent reason cited for discontinuation in trials. Whether the vascular signal attenuates with repeated use is not settled. Central effects on desire are described as emerging over weeks rather than immediately, which points to a cumulative rather than acute process.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Cyclic heptapeptide core |
| Molecular weight | 1025.2 g/mol | Calculated for the free base |
| CAS registry number | 189691-06-3 | Free base; the acetate salt has a separate entry |
| Solubility class | Water-soluble | Freely soluble in aqueous media near neutral pH |
| Typical storage | 2 to 8 °C | Protect from light; avoid repeated freeze-thaw cycles |
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
The molecular backbone consists of seven amino acid residues joined into a ring through a disulfide bridge. This cyclic conformation is critical for receptor binding. The sequence includes an acetylated N-terminus and an amidated C-terminus, modifications that improve resistance to enzymatic breakdown. One residue is in the D-configuration, a feature that further stabilizes the peptide against protease activity. Together, the ring structure and specific stereochemistry determine selectivity among melanocortin receptor subtypes.
Bremelanotide is a cyclic heptapeptide that acts as an agonist at melanocortin receptors. It binds MC1R, MC3R, MC4R, and MC5R, with MC4R activation considered most relevant to sexual desire pathways in the central nervous system. The molecule is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and energy regulation. Early research explored its use in tanning before attention shifted toward sexual dysfunction applications. Receptor binding affinity varies across these subtypes.
Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.
The melanocortin system comprises five G protein-coupled receptors, designated MC1 through MC5, that signal mainly through cyclic AMP accumulation. MC1R and MC2R are associated with pigmentation and adrenal steroid production, while MC3R and MC4R are expressed in the central nervous system and influence energy balance and behavior. MC5R appears in exocrine tissues. Natural agonists include alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone, and endogenous antagonists such as agouti-related protein modulate the same sites. This receptor family provides the framework within which bremelanotide activity is described.
Bremelanotide acts as an agonist at several melanocortin receptors, with the strongest reported activity at MC4R and measurable activity at MC1R and MC3R. Because MC4R is expressed in hypothalamic and limbic circuits, the proposed mechanism links receptor activation to modulation of central pathways involved in desire rather than to direct effects on peripheral genital tissue. The precise downstream steps remain incompletely characterized, and evidence for the involvement of specific neurotransmitters is suggestive rather than settled. Nausea and blood pressure elevation reported during trials are consistent with melanocortin signaling outside the intended target circuit.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
In nuclear physics, the Geiger–Nuttall law or Geiger–Nuttall rule relates the decay constant of a radioactive isotope with the energy of the alpha particles emitted. Roughly speaking, it states that short-lived isotopes emit more energetic alpha particles than long-lived ones. The relationship also shows that half-lives are exponentially dependent on decay energy, so that very large changes in half-life make comparatively small differences in decay energy, and thus alpha particle energy. In practice, this means that alpha particles from all alpha-emitting isotopes across many orders of magnitude of difference in half-life, all nevertheless have about the same decay energy. Formulated in 1911 by Hans Geiger and John Mitchell Nuttall as a relation between the decay constant and the range of alpha particles in air, in its modern form the Geiger–Nuttall law is
=== 210Po === Some prototype RTGs, first built in 1958 by the US Atomic Energy Commission, have used polonium-210. This isotope provides phenomenal power density (pure 210Po emits 140 W/g) because of its high decay rate, but has limited use because of its very short half-life of 138 days. A half-gram sample of 210Po reaches temperatures of over 500 °C (900 °F). As 210Po is a pure alpha-emitter and does not emit significant gamma or X-ray radiation, the shielding requirements are as low as those for 238Pu. While the short half-life also reduces the time during which accidental release to the environment is a concern, polonium-210 is extremely radiotoxic if ingested and can cause significant harm even in chemically inert forms, which pass through the digestive tract as a "foreign object". A common route of production (whether accidental or deliberate) is neutron irradiation of 209Bi, the only naturally occurring isotope of bismuth. It is this accidental production that is cited as an argument against the use of lead-bismuth eutectic as a coolant in liquid metal reactors. However, if a sufficient demand for polonium-210 exists, its extraction could be worthwhile similar to how tritium is economically recovered from the heavy water moderator in CANDUs.
(CH2CH2)O + H2O → HO–CH2CH2–OH The reaction also occurs in the gas phase, in the presence of a phosphoric acid salt as a catalyst. The reaction is usually carried out at about 60 °C (140 °F) with a large excess of water, in order to prevent the reaction of the formed ethylene glycol with ethylene oxide that would form di- and triethylene glycol:
Sources: en.wikipedia.org
The Great French Wine Blight was a severe blight of the mid-19th century that destroyed many of the vineyards in France and laid waste to the wine industry. It was caused by an insect that originated in North America and was carried across the Atlantic in the late 1850s. The actual genus of the insect is still debated, although it is largely considered to have been a species of Daktulosphaira vitifoliae, commonly known as grape phylloxera. While France is considered to have been worst affected, the blight also did a great deal of damage to vineyards in other European countries. How Phylloxera was introduced to Europe remains debated: American vines had been taken to Europe many times before, for reasons including experimentation and trials in grafting, without consideration of the possibility of the introduction of pestilence. While the Phylloxera was thought to have arrived around 1858, it was first recorded in France in 1863, in the former province of Languedoc. It is argued by some that the introduction of such pests as phylloxera was only a problem after the invention of steamships, which allowed a faster journey across the ocean, and consequently allowed pests such as the Phylloxera to survive the trip. Eventually, following Jules-Émile Planchon's discovery of the Phylloxera as the cause of the blight, and Charles Valentine Riley's confirmation of Planchon's theory, Leo Laliman and Gaston Bazille, two French wine growers, proposed that the European vines be grafted to the resistant American rootstock that were not susceptible to the Phylloxera.
Police Scotland arrest Scotland's former First Minister, Nicola Sturgeon, as part of their ongoing investigation into the SNP's finances. She is subsequently released without charge. 12 June Following a period of hot weather, thunderstorms and torrential rain bring flash flooding to parts of the UK. A mother-of-three is sentenced to 28 months in prison for inducing an abortion at home during 2020 with medication while she was 32–34 weeks pregnant. The medication was obtained following a remote consultation at which the woman misled doctors over the advancement of her pregnancy. 13 June 2023 Nottingham attacks: A major incident is declared in Nottingham, with much of the city centre cordoned off, following a vehicle-ramming and knife attack. A 31-year-old man is arrested on suspicion of multiple murders, following the deaths of three people including two university students, while three others are hospitalised. The first day of a public inquiry into the COVID-19 pandemic begins in central London. The inquiry's lead lawyer says "very little thought" was given about the impact of a national lockdown and that Brexit planning may have occupied too much of the government's time and resources, while a counsel for the Covid-19 Bereaved Families for Justice accuses the authorities of being "complacent". A heatwave is declared in several parts of the UK as temperatures reach 30 °C, and after exceeding 25 °C for three consecutive days; the UK's heat-health alert is also extended.
1940: Turkish archaeologist, Sumerologist, Assyriologist, and writer Muazzez İlmiye Çığ received her degree and began a multi-decade career at Museum of the Ancient Orient, one of three such institutions comprising Istanbul Archaeology Museums, as a resident specialist in the field of cuneiform tablets, thousands of which were being stored untranslated and unclassified in the facility's archives. In the intervening years, due to her efforts in the deciphering and publication of the tablets, the museum became a Middle Eastern languages learning center attended by ancient history researchers from every part of the world. 1941: American scientist Ruth Smith Lloyd became the first African-American woman to receive a PhD in anatomy. 1942: Austrian-American actress and inventor Hedy Lamarr and composer George Antheil developed a radio guidance system for Allied torpedoes that used spread spectrum and frequency hopping technology to defeat the threat of jamming by the Axis powers. Although the US Navy did not adopt the technology until the 1960s, the principles of their work are incorporated into Bluetooth technology and are similar to methods used in legacy versions of CDMA and Wi-Fi. This work led to their induction into the National Inventors Hall of Fame in 2014. 1942: American geologist Marguerite Williams became the first African-American woman to receive a PhD in geology in the United States. She completed her doctorate, entitled A History of Erosion in the Anacostia Drainage Basin, at Catholic University.
Sources: en.wikipedia.org
However, bicalutamide does not increase sex hormone levels if combined with adequate doses of an antigonadotropin such as a GnRH modulator, estrogen, or progestogen, due to the negative feedback effects of these medications on sex-hormone production. Because bicalutamide does not lower androgen levels, it may be a particularly favorable antiandrogen for transgender women who wish to help preserve sex drive, sexual function, and/or fertility, as antiandrogens that strongly suppress levels of testosterone and its metabolites, such as CPA and GnRH modulators, can greatly disrupt these functions. Although bicalutamide has the potential to increase testosterone levels, there is no effect of this testosterone due to the blockade of the AR by bicalutamide. Neyman and colleagues in 2019 published a study on bicalutamide as a puberty blocker in adolescent transgender girls. It was employed both alone (n=17) and in combination with estrogen (n=6) at a dose of 50 mg/day in 23 transgender girls (mean age of 16 years, range 12 to 18.4 years) between 2013 and 2018. Of the girls who were treated exclusively with bicalutamide alone, 13 returned for follow-up and were analyzed. In addition to apparently showing effectiveness as an antiandrogen and puberty blocker, bicalutamide alone increased estradiol levels and promoted feminization as a secondary effect. This included breast development to Tanner stages 2 to 5 in 85% of the patients at the first follow-up visit at 6.3 months of treatment.
== Ductal cell plasticity == There is disagreement about the plasticity potential of ductal cells in the adult pancreas. In the embryonic pancreas, the endocrine and exocrine cells originate in the pancreatic ducts as progenitor cells. In adult ductal cells, there are observations that these cells take on the identity of progenitor cells when stressed. This proposes the idea that there might be a subgroup of ductal cells that have the ability to dedifferentiate and generate endocrine cells when there is an injury to the pancreas. Essentially, ductal cells function in retaining the adult pancreas β cell mass when injured. However, there is a possibility that this capability is limited to a subtype of ductal cells only, meaning this cannot be a main pathway for pancreas regeneration.
Lectins from legume plants, such as PHA or concanavalin A, have been used widely as model systems to understand the molecular basis of how proteins recognize carbohydrates, because they are relatively easy to obtain and have a wide variety of sugar specificities. The many crystal structures of legume lectins have led to a detailed insight of the atomic interactions between carbohydrates and proteins. Legume seed lectins have been studied for their insecticidal potential and have shown harmful effects for the development of pest.
Sources: en.wikipedia.org
PT-141 was the internal development code assigned to bremelanotide during preclinical research. Reference sources sometimes index the peptide under the code rather than the generic name. The two terms describe the same molecule.
They are related but distinct cyclic peptides. Melanotan II is an earlier and less selective melanocortin analog. Bremelanotide was developed later with a narrower receptor profile and a defined clinical application.
The reviewed product is given by subcutaneous injection using a single-use autoinjector. Administration occurs under prescription supervision. The device delivers one fixed amount per use rather than a measured or adjustable quantity.
MC4R is regarded as the primary mediator on the basis of binding and functional assays. Other subtypes are also engaged, which helps explain flushing and related side effects. The step from receptor activation to reported desire change remains partly inferential.